Coronavirus Disease of 2019 (COVID-19) Health Education Initiative for School Safety
Part of paid clinical trials in Miami, Florida.
- Sponsor
- University of Miami
- Study ID
- NCT06938230
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- Health Education Initiative — BEHAVIORALParticipants will receive a one time 45 minute intervention session. During the session participants will receive information regarding COVID-19 disease process and behavioral effects and had the opportunity to ask questions.
Study Details
The purpose of this study is to compare COVID-19 knowledge, experiences, and health behaviors between participants who received the health initiative and those who did not.
Key Dates
- Start date
- Aug 2, 2022
- Status verified
- Dec 2025
- Primary completion
- Jun 10, 2023
- Completion
- Jun 10, 2023
Study Design
- Enrollment
- 112 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- HEALTH_SERVICES_RESEARCH
Arms
- Experimental: Health Education InitiativeParticipants will receive the health education session for up to 6 months.
- No Intervention: Control GroupParticipants in this group will not receive any health education and total participation is up to 6 months.
Primary Outcome Measure
Evaluation of Acceptability of Intervention as Measured by Acceptability Questionnaire [ Time Frame: Baseline ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Miami | Miami | Florida | 33136 | - |
Find similar trials in Miami, FL
By condition
By specialty
By research site
Related Studies
- Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT StudyPHASE3 · Recruiting · Ansun Biopharma, Inc. · Duarte, California
- EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe DiseasePHASE3 · Recruiting · Pfizer · Phoenix, Arizona
- Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVIDPHASE3 · Recruiting · Wes Ely · Tucson, Arizona
- Viral Infections in Healthy and Immunocompromised HostsRecruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland